Inhibikase Therapeutics IKT
NASDAQ IKT
$2.06 +0.04 (+1.98%)
At close: Sep 30, 2026 · 4:00 PM EDT

Inhibikase Therapeutics (IKT) Receivables - Other (2021)

Updated

Inhibikase Therapeutics' Receivables - Other was $217,482 in Q3 2021, down 62.9% from the prior quarter.

Analysis

Inhibikase Therapeutics (IKT) Receivables - Other (2021) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn
10 Inhibikase Therapeutics 359.62 Mn -225.86 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2021 217,482.00
Jun 30, 2021 586,581.00
Mar 31, 2021 332,774.00
API Access

Inhibikase Therapeutics Receivables - Other API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=receivables-other&ticker=IKT&period=max&api_key=YOUR_API_KEY